11:30 , Jul 9, 2019 |  BioCentury  |  Finance

Revolution raises $100M to build out Ras pipeline, explore SHP-2 combos

Following this year’s ASCO fervor around KRAS inhibitors, Revolution Medicines has raised $100 million in a series C round to advance its portfolio of Ras pathway inhibitors, including its own KRAS G12C inhibitor. The financing,...
00:25 , Jun 22, 2019 |  BC Extra  |  Financial News

Mirum, Fulcrum file for IPOs

On Friday, Mirum and Fulcrum each filed to raise up to $86.3 million in NASDAQ IPOs. Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched in November with a $120 million series A round led by New...
21:17 , Jun 20, 2019 |  BC Innovations  |  Emerging Company Profile

Casma: Tailoring autophagy targets to indications

Rather than focus on a single target, Casma is evaluating the entire autophagy pathway for a broad swath of diseases. According to Casma Therapeutics Inc. CEO Keith Dionne, inappropriate accumulation of autophagy substrates is shared...
23:44 , Jun 19, 2019 |  BC Extra  |  Company News

Management tracks: Ultragenyx promotes Erik Harris; plus F-star, Arbutus, Maze and more

Rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) promoted Erik Harris to EVP and chief commercial officer from SVP, head of North American commercial operations. Bispecific antibody company F-star Biotechnology Ltd . (Cambridge, U.K.) said CFO...
23:12 , Jun 19, 2019 |  BC Extra  |  Company News

Gilead adds targeted degradation via Nurix deal in quest to strengthen growth areas

Just three months after Daniel O'Day took the helm, Gilead has pulled the trigger on adding targeted protein degradation to its modality tool kit in areas it has tagged as growth drivers. Wednesday’s announcement of...
19:49 , Jun 7, 2019 |  BioCentury  |  Emerging Company Profile

insitro: machine learning with designated data

Just 12 months after announcing the launch of insitro, AI veteran and CEO Daphne Koller has led the drug discovery and machine learning company to a series A round of over $100 million and a...
20:45 , Jun 6, 2019 |  BC Extra  |  Financial News

How Third Rock will deploy $770M in its biggest fund yet

Staff changes and recent trends in private capital dynamics aren’t likely to sway Third Rock Ventures’ strategy as it invests its new $770 million Fund V, the firm’s largest-ever vehicle. The firm will, however, have...
18:02 , May 31, 2019 |  BC Extra  |  Clinical News

Grail unveils competitive ASCO data from second substudy of CCGA trial

Just a day after the launch of the latest liquid biopsy company, data from Grail show it will be a tight race to develop a multicancer liquid biopsy test for early cancer detection -- and...
14:58 , May 30, 2019 |  BioCentury  |  Emerging Company Profile

Thrive’s quest to bring multicancer liquid biopsy test into routine clinical use

With Third Rock leading the way in a $110 million series A, newly launched Thrive is banking that a multi-analyte approach to liquid biopsy could give it an edge in creating a test that is...
21:53 , May 29, 2019 |  BC Extra  |  Company News

Management tracks: Gilead replaces Hamill with BMS's Mercier; plus Alnylam, Audentes and more

Gilead Sciences Inc. (NASDAQ:GILD) hired Johanna Mercier as chief commercial officer, effective July 1, to assume the responsibilities of Laura Hamill, who is leaving nine months after joining the company as EVP of worldwide commercial...